Wrongs known as right in thyroid scintigraphy and uptake study
Methods: Thyroid hyperactive and hypoactive nodule models were created using 4 mCi (148 MBq) 99mTc-pertechnetate. In the experimental model, 4 mm, 6 mm and 8 mm diameter pin-hole collimators, and 5 cm, 7 cm and 10 cm object-to-pinhole distances were investigated.
Results: In thyroid hyperactive nodule model, despite the same activity value, uptake at 7 cm object-to-pinhole distance was higher compared to 10 cm distance (122% and 103%, respectively). In the patient with Graves’ disease, despite the same activity value, uptake at 5 cm object-to-pinhole distance was higher compared to 10 cm distance (8% and 4%, respectively). In thyroid hypoactive nodule model, 4 mm, 6 mm and 8 mm diameters pin-hole collimators were imaged at 5 cm, 10 cm and 15 cm object-to-pinhole distances. The resolution differences between the images were evaluated.
Conclusion: It was determined that imaging using 10 cm object-to-pinhole distanceand 4 mm diameter pin-hole collimator was best in terms of image resolution and optimum 99mTc-pertechnetate uptake level.
[1] Higgins HP, Ball D, Eastham S. 20-Min 99mTc thyroid uptake: a simplified method using the gamma camera. J Nucl Med 1973;14:907-11.
[2] Schneider PB. Simple, rapid thyroid function testing with 99mTc-pertechnetate thyroid uptake ratio and neck/thigh ratio. Am J Roentgenol 1979;132:249-353.
[3] Becker D, Charkes ND, Dworkin H, Hurley J, McDougall IR, Price D, et al. Procedure guideline for thyroid uptake measurement: 1.0. Society of Nuclear Medicine. J Nucl Med 1996;37:1266-8.
[4] Ziessman HA, Fahey FH, Gochoco JM. Impact of radiocontaminants in commercially available iodine-123: dosimetric evaluation. J Nucl Med 1986;27:428-32.
[5] Ramos CD, Zantut-Wittmann DE, Tambascia MA, Assumpcao L, Etchebehere EC, Camargo EE. Thyroid suppression test with L-thyroxine and [99mTc] pertechnetate. Clin Endocrinol (Oxf) 2000;52:471-7.
[6] Anjos DA, Etchebehere EC, Santos AO, Lima MC, Ramos CD, Paula RB, et al. Normal values of [99mTc] pertechnetate uptake and excretion fraction by major salivary glands. Nucl Med Commun 2006;27:395-403.
[7] Smith JJ, Croft BY, Brookeman VA, Teates CD. Estimation of 24-hour thyroid uptake of I-131 sodium iodide using a 5-minute uptake of technetium-99m pertechnetate. Clin Nucl Med 1990;15:80-3.
[8] Gullberg GT, Zeng GL, Datz FL, Christian PE, Tung CH, Morgan HT. Review of convergent beam tomography in single photon emission computed tomography. Phys Med Biol 1992;37:507-34.
[9] Anger K, Feine U, Kaiser E. Improved quality of thyroid scintigrams by using a gamma camera with pin-hole collimator. Rofo 1981;135:188-92.
[10] Tai YC, Wu H, Pal D, O’Sullivan JA. Virtual-Pinhole PET. J Nucl Med 2008;49:471-9.
[11] Selby JB, Buse MG, Gooneratne NS, Moore DO. The Anger camera and the pertechnetate ion in the routine evaluation of thyroid uptake and imaging. Clin Nucl Med 1979;4:233-7.
[12] Volckaert V, Vandermeulen E, Duchateau L, Saunders JH, Peremans K. Inter- and intraobserver variability of (semi-) quantitative parameters commonly used in feline thyroid scintigraphy. Res Vet Sci 2016;105:87-91.
[13] Ramos CD, Zantut Wittmann DE, Etchebehere EC, Tambascia MA, Silva CA, Camargo EE. Thyroid uptake and scintigraphy using 99mTc pertechnetate: standardization in normal individuals. Sao Paulo Med J 2002;120:45-8.
[14] Sarkar SD. Benign thyroid disease: what is the role of nuclear medicine? Semin Nucl Med 2006;36:185-93.
[15] Clerc J. Imaging the thyroid in children. Best Pract Res Clin Endocrinol Metab 2014;28:203-20.
[16] Biassoni L, Easty M. Paediatric nuclear medicine imaging. Br Med Bull 2017;123:127-48.
[17] Alimanovic-Alagic R, Brkovic A, Kucukalic-Selimovic E. Evaluation of thyroid diseases in nuclear medicine. Med Arh 2008;62:303-6.
[18] Töre G, Karayalçın B, Esen B, Türkmen C, Yüksel D, Varoğlu E, et.al. Tiroit sintigrafisi uygulama kılavuzu. Turk J Nucl Med 2003;12:178-80.
[19] Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 2002;43:1188-200.
[20] Chung JK, Youn HW, Kang JH, Lee HY, Kang KW. Sodium iodide symporter and the radioiodine treatment of thyroid carcinoma. Nucl Med Mol Imaging 2010;44:4-14.
[21] Ogawa K, Hashimoto J, Kubo A, Hashimoto S, Suzuki K, Ruike T. Development of a converging collimator for thyroid scintigraphy. KakuIgaku 1990;27:303-11.
[22] Meier DA, Kaplan MM. Radioiodine uptake and thyroid scintiscanning. Endocrinol Metab Clin North Am 2001;30:291-313.
[23] Franklyn JA. What is the role of radioiodine uptake measurement and thyroid scintigraphy in the diagnosis and management of hyperthyroidism. Clin Endocrinol (Oxf) 2010;72:11-2.
[24] Green CH. Technetium-99m production issues in the United Kingdom. J Med Phys 2012;37:66-71.
[25] Shapiro B, Zanin DE, Schipper R. Reference-free thyroid uptake measurement. Nucl Med Commun 2014;35:382-90.
[26] Meier DA, Brill DR, Becker DV, Clarke SE, Silberstein EB, Royal HD, et al. Procedure guideline for therapy of thyroid disease with (131) iodine. J Nucl Med 2002;43:856-61.
[27] Lee H, Kim JH, Kang YK, Moon JH, So Y, Lee WW. Quantitative single-photon emission computed tomography/computed tomography for technetium pertechnetate thyroid uptake measurement. Medicine (Baltimore) 2016;95:e4170.
[28] Pelletier-Galarneau M, Martineau P, Klein R, Henderson M, Zuckier LS. Reproducibility of radioactive iodine uptake (RAIU) measurements. J Appl Clin Med Phys 2018;19:239-42.
Copyright (c) 2019 The European Research Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloads
Article Information
- Article Type Research Article
- Submitted February 21, 2026
- Published January 3, 2019
- Issue Vol. 5 No. 1 (2019)
- Section Research Article
